Looks like they are getting less money up front now. The original deal was for up to US$150 million in upfront and milestone payments prior to product launch but that has been reduced to US$112.5 million. Though it is good that they feel confident to move forward with the program, and that Grünenthal are sticking around.
Ann: Mesoblast Update on Chronic Low Back Pain Program, page-4
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.015(1.33%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.14 | $1.11 | $1.498M | 1.334M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 15282 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 31844 | 15 |
View Market Depth
| Last trade - 11.51am 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
-0.015 ( 0.77 %) |
||||
| Open | High | Low | Volume | ||
| $1.13 | $1.14 | $1.11 | 278098 | ||
| Last updated 12.11pm 05/06/2024 ? | |||||
| MSB (ASX) Chart |